Amgen Inc. reported its first-quarter 2025 financial results, surpassing analyst expectations with adjusted earnings per share (EPS) of $4.90 compared to the anticipated $4.30. The company's revenue reached $8.15 billion, slightly above the forecasted $8.06 billion, marking a 9% increase from the first quarter of 2024. GAAP EPS improved to $3.20 from a loss of $0.21 in the same period last year. Amgen reaffirmed its full-year 2025 guidance with adjusted EPS projected between $20.00 and $21.20, and revenue expected to range from $34.3 billion to $35.7 billion, closely aligning with estimates. Meanwhile, Motorola Solutions Inc. also posted first-quarter results exceeding expectations, with adjusted EPS of $3.18 versus an estimate of $3.01 and revenue of $2.53 billion slightly above the $2.52 billion forecast. The company reported record Q1 sales, operating earnings, and cash flow driven by strong demand in North America and new AI-powered product launches. However, Motorola Solutions forecasted a weaker second-quarter profit due to tariff uncertainties. The company maintained its full-year 2025 adjusted EPS guidance between $14.64 and $14.74 and sales guidance of $11.41 billion, both near analyst estimates. Additional companies such as Ardelyx, Ascendis Pharma, Douglas Elliman Inc., Amneal, Butterfly Network, Cinemark Holdings, Fulgent, Forge Global Holdings, Modiv Industrial, TaskUs, and Mogo announced or scheduled upcoming first-quarter 2025 financial results releases. Several pharmaceutical and biotech firms, including Kura Oncology, Corcept Therapeutics, Wave Life Sciences, Praxis Precision Medicines, CRISPR Therapeutics, and Ascendis Pharma, highlighted upcoming regulatory filings, clinical trial data presentations, and product approval milestones scheduled throughout 2025.